markets is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Fermi Inc., the most common co-covered peer. Each story carries 4 original sources on average, compared with 2.9 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Mereo BioPharma Group plc
markets is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Fermi Inc., the most common co-covered peer. Each story carries 4 original sources on average, compared with 2.9 for the broader beat in this window. At 5, the average consequence score sits below the same-window beat average of 6.2. We currently track 1 Finance story that mention Mereo BioPharma Group plc, all published on March 5, 2026.
Stories tracked
1
Sources per story
4
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 98 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Mereo BioPharma Group plc. Shared-story counts are live from our verified record — not editorial picks.
Pomerantz Law Firm has issued urgent reminders for investors regarding class action lawsuits against Ultragenyx Pharmaceutical, Fermi Inc., Mereo BioPharma, and Navan, Inc. These legal actions target alleged securities fraud and disclosure failures, setting critical deadlines for lead plaintiff applications.
Mereo BioPharma Group plc is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.